Met Life Investment Management, LLC Arcellx, Inc. Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 24,981 shares of ACLX stock, worth $2.07 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,981
Previous 19,594
27.49%
Holding current value
$2.07 Million
Previous $1.36 Million
1.17%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding ACLX
# of Institutions
173Shares Held
45.6MCall Options Held
53.6KPut Options Held
53.7K-
Perceptive Advisors LLC New York, NY3.89MShares$322 Million6.21% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.85MShares$318 Million8.59% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$310 Million19.51% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$291 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$194 Million56.87% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.63B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...